The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation
- PMID: 11528419
- DOI: 10.1038/nn0901-887
The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation
Abstract
Several pathogenic Alzheimer's disease (AD) mutations have been described, all of which cause increased amyloid beta-protein (Abeta) levels. Here we present studies of a pathogenic amyloid precursor protein (APP) mutation, located within the Abeta sequence at codon 693 (E693G), that causes AD in a Swedish family. Carriers of this 'Arctic' mutation showed decreased Abeta42 and Abeta40 levels in plasma. Additionally, low levels of Abeta42 were detected in conditioned media from cells transfected with APPE693G. Fibrillization studies demonstrated no difference in fibrillization rate, but Abeta with the Arctic mutation formed protofibrils at a much higher rate and in larger quantities than wild-type (wt) Abeta. The finding of increased protofibril formation and decreased Abeta plasma levels in the Arctic AD may reflect an alternative pathogenic mechanism for AD involving rapid Abeta protofibril formation leading to accelerated buildup of insoluble Abeta intra- and/or extracellularly.
Comment in
-
Protofibrils, the unifying toxic molecule of neurodegenerative disorders?Nat Neurosci. 2001 Sep;4(9):859-60. doi: 10.1038/nn0901-859. Nat Neurosci. 2001. PMID: 11528409 No abstract available.
Similar articles
-
Unique physicochemical profile of beta-amyloid peptide variant Abeta1-40E22G protofibrils: conceivable neuropathogen in arctic mutant carriers.J Mol Biol. 2004 May 21;339(1):145-59. doi: 10.1016/j.jmb.2004.03.028. J Mol Biol. 2004. PMID: 15123427
-
Sensitive ELISA detection of amyloid-beta protofibrils in biological samples.J Neurochem. 2007 Oct;103(1):334-45. doi: 10.1111/j.1471-4159.2007.04759.x. Epub 2007 Jul 10. J Neurochem. 2007. PMID: 17623042
-
The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase.J Neurochem. 2007 May;101(3):854-62. doi: 10.1111/j.1471-4159.2006.04443.x. J Neurochem. 2007. PMID: 17448150
-
beta-Secretase, APP and Abeta in Alzheimer's disease.Subcell Biochem. 2005;38:79-103. Subcell Biochem. 2005. PMID: 15709474 Review.
-
[Advances in molecular biology and clinical study of amyloid precursor protein for Alzheimer's disease].Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004 Apr;26(2):201-9. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004. PMID: 15171563 Review. Chinese.
Cited by
-
A Novel Drosophila Model of Alzheimer's Disease to Study Aβ Proteotoxicity in the Digestive Tract.Int J Mol Sci. 2024 Feb 9;25(4):2105. doi: 10.3390/ijms25042105. Int J Mol Sci. 2024. PMID: 38396782 Free PMC article.
-
Misfolded protein oligomers: mechanisms of formation, cytotoxic effects, and pharmacological approaches against protein misfolding diseases.Mol Neurodegener. 2024 Feb 20;19(1):20. doi: 10.1186/s13024-023-00651-2. Mol Neurodegener. 2024. PMID: 38378578 Free PMC article. Review.
-
Odor Identification Across Time in Mutation Carriers and Non-Carriers in Autosomal-Dominant Alzheimer's Disease.J Alzheimers Dis. 2024;97(2):587-598. doi: 10.3233/JAD-230618. J Alzheimers Dis. 2024. PMID: 38160354 Free PMC article.
-
A light at the end of the tunnel - from mutation identification to a potential treatment for Alzheimer's disease.Ups J Med Sci. 2023 Nov 28;128. doi: 10.48101/ujms.v128.10316. eCollection 2023. Ups J Med Sci. 2023. PMID: 38084203 Free PMC article. Review.
-
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease.BioDrugs. 2024 Jan;38(1):5-22. doi: 10.1007/s40259-023-00633-2. Epub 2023 Nov 13. BioDrugs. 2024. PMID: 37955845 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
